TORONTO, Jan. 10 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) announced
today that its Chief Operating Officer, Peter Tassiopoulos, will
succeed Radu Leca as Chief Executive Officer effective today. The
announcement finalizes a transition process that has been planned for
several months. The appointment was proposed by Dr. Leca and
unanimously adopted by the Board of Directors. Dr. Leca will continue
to serve as the President of Biosign.
Mr. Tassiopoulos has served as Biosign Technologies' Chief Operating
Officer since 2009. Mr. Tassiopoulos has over 20 years of experience in
business development, sales management, global distribution networks
and marketing alliances with Avaya, France Telecom, Bell Canada, Mitel,
and GE Healthcare. A recognized expert in digital healthcare
technology, Mr. Tassiopoulos has served on various panels at the United
Nations, including Mobile Health Management.
"Peter has been actively involved in the leadership and key decisions at
Biosign since 2009. He brings relevant business experience, decisive
leadership, and continuity to this critical role for the company," said
David Silver, Biosign's Chairman. "The Board of Directors deeply
appreciates the leadership and contributions that Radu has provided
since founding the company in 2006. We are pleased with the serious
commitment Peter is making to the company and look forward to Biosign's
rapid growth under his leadership."
"Peter is exactly what Biosign needs, at exactly the right time", stated
Dr. Leca. "He became my apparent successor in 2009, when he joined us
as Chief Operating Officer. Our work together has prepared him for this
moment, and I am confident that his tenure will be as remarkable as his
conviction and passion for the lasting mark that Biosign will make on
"There are remarkable opportunities ahead for Biosign, and I am honored
to lead the company through the next chapter of its corporate
progression - large-scale commercialization - while enabling Radu to
concentrate on advancing our deep product pipeline", said Peter
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key
applications include intelligent systems for noninvasive monitoring of
common health risks associated with blood pressure, glucose, and
medication. The core technology combines measurement, analysis, and
rapid knowledge formation to support health monitoring across global
markets. The UFIT(R) medical device technology powers quality data
collection and analytics for clinical diagnostics, self-care, wellness,
disease state evaluation & management, and remote patient monitoring.
For more information on Biosign, please visit www.biosign.com.
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
"Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release."
SOURCE Biosign Technologies Inc.
For further information:
|Scott Worthington, CFO |
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 224
| || || || || || || || || ||Alan S. Roemer, SVP|
The Trout Group LLC
Phone: 646 378-2900
Email : email@example.com